logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

The XBiotech Interesting News That Rallied Its Stock

XBiotech XBiotech ( XBIT ), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and complexity of biological drug production. XBiotech  is dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. The firm is currently advancing...

Read More

January 14, 2020

0

ViiV Healthcare: The FDA Approved Cabenuva for Adults Who are HIV Virologically-Suppressed

ViiV Healthcare Announced FDA Approval for Cabenuva for Adults with HIV-1 From London we learned that ViiV Healthcare announced that the US Food and Drug Administration ( FDA ) approved Cabenuva, the first and only complete long-acting regimen for the...

Read More

January 25, 2021

0

Vertex and CRISPR Therapeutics: The EMA Granted PRIME Designation to CTX001. Read Also: Cassava Sciences Encouraging News

Vertex and CRISPR Granted PRIME Designation from the EMA for CTX001 Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP ) announced that the European Medicines Agency ( EMA ) granted Priority Medicines ( PRIME ) designation to CTX001, an...

Read More

April 26, 2021

0

Nektar Is Still a Favorite

Nektar in the NEWS T he FDA's Anesthetic and Analgesic Advisory Committee ( AADPAC ) and Drug Safety and Risk Management Advisory Committee ( DSaRM ) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ ( NKTR ) New Drug Application (...

Read More

January 15, 2020

0

Midday January 16, 2020 Outperforming Prohost Picks

Outperforming Prohost Picks  January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 AMGN Trading at $243.50 UP $1.80 FTSV  Trading at $40.00 UP $3.20 RETA Trading at $217.01 UP $4.56 ALNY Trading at $119.26 UP $1.17...

Read More

January 16, 2020

0

Why Moderna Stock Is Rallying

In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has killed 17 and sickened hundreds of people in China. According to officials the first US case is of a very healthy 30 year old...

Read More

January 22, 2020

0

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab's Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL CASI Pharmaceuticals ( CASI ) partner BioInvent International ( BINV ) announced positive interim results from the Phase I/IIa trial of the novel anti-FcγRIIB product BI-1206 when combined with...

Read More

January 28, 2021

0

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer's Patients Following Six Months of Treatment

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences ( SAVA ) announced impressive results of an interim analysis from an open-label study of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam improved both patients’ cognition and...

Read More

February 2, 2021

0

Roche and Spark Therapeutics: Gene Therapy SPK-8016 Demonstrating Promising Results on Adults with Severe Hemophilia A

Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results Looking for gene therapy treatments for chronic debilitating life-threatening diseases we fell on news from Spark Therapeutics, a member of the Roche Group ( RHHBY ) ;   the firm...

Read More

February 5, 2021

0

The European Medicine Agency Validates the Gilead Application for a CAR T Product for Mantle Cell Lymphoma

The EMA validated the MAA for the Gilead Investigational CAR T Product for MCL Kite , a  Gilead ( GILD ) company, announced that the European Medicines Agency ( EMA ) has validated the Marketing Authorization Application ( MAA )...

Read More

January 29, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 110
  • 111
  • 112
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy